EGFR expression

P1/2, N=144, Recruiting, Engeneic Pty Limited | Not yet recruiting --> Recruiting

Molecular docking results showed that ertugliflozin had the strongest intermolecular binding to EGFR and that ertugliflozin improved the viability of high-glucose (HG)/high-lipid combined hypoxia-reoxygenation-injured (HG/HP + H/R) cardiomyocytes and inhibited EGFR expression in cardiomyocytes...Molecular docking and cell experiments further confirmed that SGLT2i-ERTU improves HG/HP + H/R myocardial cell injury by targeting EGFR. Our study deepened the pharmacological mechanism of SGLT2is in the treatment of T2DM combined with CHD and provided a new perspective and therapeutic basis for future experimental research and healthcare.

P=N/A, N=200, Recruiting, Dalian Medical University First Affiliated Hospital; Dalian Medical University First Affiliated Hospital

P2/3, N=737, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

P1, N=36, Not yet recruiting, Shanghai East Hospital; Jing Medicine Technology (Shanghai) Co., Ltd.

P1, N=444, Not yet recruiting, Fudan University Shanghai Cancer Center; CSPC Zhongqi Pharmaceutical Technology Co., Ltd.

We targeted T and NK92 ACDVs to cancer cells possessing the xenoantigen, N-glycolyl neuraminic acid GM3 ganglioside, using the 14f7hT antibody or the tumour antigen, epidermal growth factor receptor, using the nimotuzumab antibody...14F7hT-conjugated NK92 ACDVs showed cytotoxic activity against chronic lymphocytic leukaemia biopsies. This research shows the potential for using antibody-conjugated, cytotoxic T and NK ACDVs as a feasible and effective approach for tumour-targeted immunotherapy.

The multimodal therapeutic approach included one attempted VAC cycle (discontinued due to Grade 4 neutropenia), five cycles of single-agent doxorubicin, and subsequent administration of toceranib with dose reduction for anemia...Postmortem extended immunohistochemistry demonstrated heterogeneous receptor tyrosine kinase (RTK) expression: EGFR and VEGFR positivity, strong membranous HER2 labeling in approximately 60% of tumor cells, low KIT expression, and negative PDGFR. This case underscores the aggressive metastatic nature of primary hepatic hemangiosarcoma following rupture and highlights practical considerations for systemic therapy selection and adverse event monitoring in clinical practice.

EGF/EGFR expression is associated with immunosuppressive microenvironments and adverse outcomes in HGG. Radiomics may provide a non-invasive approach for estimating EGFR expression, although model performance requires external validation and EGFR-ADCs showed partial inhibitory activity within the tested range, though potency remains to be defined.These findings suggest a framework into radiogenomic stratification and targeted therapy in GBM.

Berberine altered the microtubule cytoskeleton similarly to vincristine...Their relationship to berberine and its derivatives is novel. Berberine-type compounds may be new candidates against cancer; however, they may develop drug resistance.

Histological study revealed decreased mitotic activity and large tumor cells, with minimal systemic damage. GNS-PKs-pullulan microneedle system offers a hope for an innovative, potent, effective, and non-invasive strategy for breast cancer treatment with high antitumor efficacy.

Our findings demonstrate that tumor-derived exosomes engineered with EGF on their surface enable targeted drug delivery to tumors with high EGFR expression. Although the exosomes modestly increase cell proliferation in vitro, the EGF-Exo-DOX formulation exhibits enhanced tumor accumulation relative to the heart, minimal cardiac uptake, and shows no tumorigenic effects in vivo. Compared to Lipo-DOX, a widely used clinical formulation of liposomal DOX in China, EGF-Exo-DOX demonstrates superior cellular uptake, greater induction of tumor cell apoptosis, and improved anti-tumor efficacy. These results highlight the potential of engineered exosomes as a targeted drug delivery platform for patients with EGFR-overexpressing tumors.